We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+61.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$936M
AUM Growth
+$589M
Cap. Flow
+$339M
Cap. Flow %
36.25%
Top 10 Hldgs %
80.61%
Holding
67
New
28
Increased
19
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$122M
2
CATX icon
Perspective Therapeutics
CATX
+$37.6M
3
ORKA
Oruka Therapeutics
ORKA
+$29.9M
4
JBIO
Jade Biosciences
JBIO
+$20.3M
5
ELVN icon
Enliven Therapeutics
ELVN
+$18.3M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$10.4M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.35M
3
MCK icon
McKesson
MCK
+$7.81M
4
A icon
Agilent Technologies
A
+$5.65M
5
PFE icon
Pfizer
PFE
+$5.07M

Sector Composition

Rank Sector Weight
1 Healthcare 99.4%
2 Consumer Staples 0.39%
3 Consumer Discretionary 0.21%

No holdings matched the selected filter criteria.

1 2 3

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2026 Portfolio in Review

As of Q1 2026, Avidity Partners Management held 67 positions worth $936M, up 170% from $347M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Avidity Partners Management deployed $339M of net new capital in Q1 2026, opening 28 new positions and adding to 19 existing holdings. Its largest new stake was Aktis Oncology: 937,132 shares worth $17.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was CG Oncology, an estimated $10.4M trimmed.

  • Avidity Partners Management's largest Q1 2026 buy was Aktis Oncology: 937,132 shares worth $17.2M.
  • Avidity Partners Management added most to Dianthus Therapeutics in Q1 2026, an estimated $122M increase.
  • Avidity Partners Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $10.4M.
  • Avidity Partners Management fully exited Alnylam Pharmaceuticals in Q1 2026, selling an estimated $8.35M.
  • Avidity Partners Management's ten largest holdings make up 81% of its $936M portfolio in Q1 2026.
  • Avidity Partners Management opened 28 new positions and closed 15 in Q1 2026.
  • Avidity Partners Management's portfolio value rose 170% quarter-over-quarter to $936M.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.